News release
Apr 30, 2017

Neem Biotech awarded at Medilink UK Awards for work on cystic fibrosis


Neem was recognised with a Runner-Up award in the Innovation Award category at the recent Medilink UK Awards 2017 ceremony. The award was bestowed for Neem Biotech’s groundbreaking work in developing a bioactive compound that can be used together with commonly prescribed antibiotics to control the chronic lung infections that are the largest cause of death in people with cystic fibrosis. This compound controls the proliferation of the biofilm layer that the Pseudomonas aeruginosa bacteria secrete to protect themselves against the effects of the prescribed antibiotics. Neem Biotech’s ongoing development of this compound, as well as the Orphan Drug Designation received from the FDA for this intervention have now been acknowledged at the Medilink UK Awards.

 

< BACK < BACK

News release
Apr 30, 2017

Neem Biotech awarded at Medilink UK Awards for work on cystic fibrosis


Neem was recognised with a Runner-Up award in the Innovation Award category at the recent Medilink UK Awards 2017 ceremony. The award was bestowed for Neem Biotech’s groundbreaking work in developing a bioactive compound that can be used together with commonly prescribed antibiotics to control the chronic lung infections that are the largest cause of death in people with cystic fibrosis. This compound controls the proliferation of the biofilm layer that the Pseudomonas aeruginosa bacteria secrete to protect themselves against the effects of the prescribed antibiotics. Neem Biotech’s ongoing development of this compound, as well as the Orphan Drug Designation received from the FDA for this intervention have now been acknowledged at the Medilink UK Awards.